Management

Dr. Arora brings over 20 years of research and development experience in pharmacology and toxicology spanning early drug discovery to IND-enabling non-clinical programs to support global regulatory submissions for commercial therapeutics including Xembify®, Prolastin-C® and HyperRAB®. Dr. Arora joins Opus following 11 years of leadership at Grifols where he led late-stage discovery research and subsequent development aspects of R&D projects, including pharmacology/toxicology, pharmacokinetics and viral safety for candidates in the pipeline. He also acted as the lead non-clinical R&D representative to regulatory agencies. Prior to Grifols, Dr. Arora served as Director of Pharmacology & Toxicology at Talecris Biotherapeutics, Principal Research Scientist at Bayer HealthCare, and Team Leader and Post-Doctoral Fellow at AVI BioPharma (now Sarepta Therapeutics) where he conducted preclinical studies leading to some of the earliest first-in-human trials of antisense-based gene therapies. Dr. Arora is a published investigator and patent holder in the areas of pharmacology, toxicology, genetics, drug metabolism and pharmacokinetics. He earned his PhD in Pharmacology and Toxicology from the University of Nebraska Medical Center and a B.S. in Human Biology from the All India Institute of Medical Sciences.